Global News | Astellas

Month Year

Jul 1, 2015

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more
Jul 1, 2015

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more
Jun 15, 2015

Results of Additional Analysis of Data from Japanese Clinical Trial of Anti-TNF-alpha Antibody Certolizumab Pegol Announced at 2015 EULAR Annual European Congress of Rheumatology

Read more
Jun 2, 2015

Astellas and Anokion to Collaborate on Immune Tolerance Therapeutics - Kanyos Bio established to develop products for Celiac Disease and Type 1 Diabetes -

Astellas Pharma Inc. (“Astellas”; TSE 4503, headquarters: Tokyo; President and CEO Yoshihiko Hatanaka) and Anokion SA (“Anokion“, headquarters: Lausanne; Chairman Jeffrey A. Hubbell) today...

Read more
Jun 2, 2015

NEW ENZALUTAMIDE DATA IN TRIPLE-NEGATIVE BREAST CANCER PRESENTED AT THE 2015 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

TOKYO and NORTHBROOK, Ill. – June 1, 2015 – Astellas Pharma Inc. (Tokyo: 4503) announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for...

Read more
Jun 1, 2015

Astellas Announces Status of Acquisition of Own Shares

Read more
May 30, 2015

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability and Efficacy Data for ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Read more
May 27, 2015

Strategic Plan 2015-2017

Building Resilience for Sustainable Growth

Read more
May 26, 2015

Astellas: Strategic Plan 2015-2017

Read more
May 26, 2015

Announcement of Approval of Additional Indication for the TNF-α inhibitor Certolizumab Pegol (Generic Name) in Japan

Read more
May 26, 2015

Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan

Read more
May 26, 2015

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more
May 17, 2015

Mirabegron as Add-on Treatment to Solifenacin Therapy Demonstrated Superior Results to Solifenacin Monotherapy in Beside Trail

Data Presented in Pienary Sessions at AUA 2015

Read more
May 11, 2015

Astellas Announces Cancellation of Treasury Shares

Read more
May 11, 2015

Notice Regarding the Introduction of a Performance-linked Stock Compensation Scheme

Read more
May 8, 2015

Astellas Supports Nepal Earthquake Relief Efforts

Tokyo, May 8, 2015– Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, “Astellas”) would like to express our deepest sympathy to the victims of Nepal...

Read more
Apr 24, 2015

Astellas Announces Personnel Change

Read more
Apr 23, 2015

The Results of Japanese Clinical Trials of Anti-TNF-alpha Antibody Certolizumab Pegol were Announced at Leading Rheumatology Meeting 2015 in Japan

Tokyo, Japan, 23 April, 2015-The additional analyses of C-OPERA, and long-term safety and efficacy over 4 years in J-RAPID and HIKARI studies were reported at the Annual General Assembly and...

Read more
Apr 23, 2015

Astellas Announces Consolidated Business Forecasts for Fiscal Year 2014

Read more
Apr 23, 2015

Astellas Nominates Director and Audit & Supervisory Board Member

Read more
Apr 22, 2015

Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics - Exclusive Collaboration Includes Option for Astellas to Acquire Potenza -

Tokyo and Cambridge, MA – April 22, 2015 -- Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today...

Read more
Apr 15, 2015

MSD and Astellas sign a memorandum of understanding regarding co-development and co-commercialization of combination product of JANUVIA® and Suglat®, oral treatments for type 2 diabetes

MSD K.K. (Head office: Tokyo; President: Tony Alvarez) and Astellas Pharma Inc. (Head office: Tokyo; President: Yoshihiko Hatanaka) signed a memorandum of understanding regarding co-development...

Read more
Apr 3, 2015

MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia

TOKYO and HOUSTON – April 3, 2015 – Astellas Pharma Inc. (TSE: 4503) and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and...

Read more
Apr 3, 2015

ENZALUTAMIDE DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION FREE SURVIVAL COMPARED WITH BICALUTAMIDE IN STRIVE TRIAL

SAN FRANCISCO, CA and TOKYO, JAPAN – April 2, 2015 – Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced topline results from the Phase 2 STRIVE trial...

Read more
Apr 1, 2015

Astellas Celebrates 10th Anniversary

Tokyo, Japan, April 1, 2015 – Astellas Pharma Inc. (Tokyo:4503,“Astellas”) is pleased to announce that the Company will mark its 10th anniversary on April 1, 2015. Since being established in...

Read more

Show per page

Choose Language

News